6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SUN-057 Familial Partial Lipodystrophy Presenting As Recurrent Acute Pancreatitis- Challenges In Management

      abstract
      , MD, , MD, , MD, , MD
      Journal of the Endocrine Society
      Endocrine Society

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hypertriglyceridemia is a commonly encountered condition for health care providers, it is defined by a fasting serum triglyceride level of more than 150 mg/dl. However, more severe hypertriglyceridemia >1000 mg/dl is rare and found usually in less 1/5000 individuals. (Ford ES, et al, 2009) hypertriglyceridemia can be secondary to few diseases among which is familial lipodystrophy. Triglyceride level of more than 1000 mg/dl is associated with acute pancreatitis, and the risk increases dramatically with increasing triglyceride level to above 2000 mg/dl (reaching 20%) (Scherer J, et al,2014). We present a 39-year-old Caucasian male patient who started to have recurrent acute pancreatitis at the age of 18, investigations for the common causes of acute pancreatitis was unremarkable, except for triglyceride level of 20,000 mg/dl. Genetic testing was consistent with familial partial lipodystrophy. Management initially consisted of plasmapheresis to control the acute episode, in addition to lipid lowering agents (Statin, fenofibrate, and omega-3-acid) .despite being on maximal medical therapy, he required plasmapheresis on weekly basis.His physical exam was remarkable for loss of adipose tissue in the lower extremities and excess adipose tissue deposit in the supra-clavicular area. other metabolic complications included severe insulin resistance and difficult to control DM, and NASH that is progressing to chronic liver disease. The hallmark of lipodystrophy syndromes in general is the selective loss of adipose tissue, which can be partial or complete. Lipodystrophy syndromes are divided into congenital and acquired. Acquired lipodystrophy is most commonly seen is the lipodystrophy secondary to HIV antiretroviral medications (protease inhibitors)(Garg A et.al ,2011). Congenital lipodystrophy remains rare. Our patient has Partial familial lipodystrophy (PFLD), as evident by his physical exam findings. FPLD is also associated with other metabolic abnormalities include hyperglycemia, insulin resistance, increased metabolic rate, and hypertriglyceridemia and that can be severe as in this patient. Conclusion: untreated severe hypertriglyceridemia is an independent risk factor for CAD, as well as a cause of recurrent pancreatitis, which is associated with significant morbidity and mortality, evaluation for secondary causes helps guide the management and prevent serious complications and recurrence.

          Related collections

          Author and article information

          Journal
          J Endocr Soc
          J Endocr Soc
          jes
          Journal of the Endocrine Society
          Endocrine Society (Washington, DC )
          2472-1972
          15 April 2019
          30 April 2019
          : 3
          : Suppl 1 , ENDO 2019 Abstracts - 101st Annual Meeting of the Endocrine Society – March 23 – 26th, 2019 – New Orleans, Louisiana
          : SUN-057
          Affiliations
          [_1]University of Toledo, Toledo, OH, United States
          Article
          js.2019-SUN-057
          10.1210/js.2019-SUN-057
          6553302
          8917adb4-2cc4-4637-bb12-06010d121da2
          Copyright © 2019 Endocrine Society

          This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).

          History
          Categories
          Cardiovascular Endocrinology
          Endocrine Regulation of Cardiovascular Disease: Hormones and Lipids

          Comments

          Comment on this article